HCPCS Level II code J9356 represents a subcutaneous formulation of trastuzumab combined with hyaluronidase (10 mg per unit) used in oncology care. The code identifies a biologic injectable therapy administered to patients who require HER2-directed treatment, and it matters nationally as trastuzumab products are central to breast and gastric cancer management and drive notable oncology drug spending and site-of-care decisions. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will learn what this code denotes clinically and operationally, how it aligns with outpatient and office-based subcutaneous administration, and the payer landscape relevant to coverage and billing practice. The publication summarizes available benchmarks for utilization and reimbursement, notes common billing and coding considerations for administration in ambulatory oncology settings, and outlines policy and regulatory contexts that affect access and payment for trastuzumab subcutaneous formulations. Data gaps from the input are identified where applicable; specifics on modifiers, associated taxonomies, ICD-10 pairings, and related codes are not provided in the source and are noted as unavailable.